Moffitt researchers, with patience at the forefront, tackle a difficult issue that, undetected, makes treating cancer more ...
Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among women of African ancestry. This is often due to a combination of factors, ...
CLAIRITY BREAST provides clinicians with a first-in-class, novel platform for identifying future risk of breast cancer CLAIRITY BREAST analyzes subtle imaging features on screening mammograms that ...
Re-prompting for ESR1 mutations in breast cancer: Improving mutation reporting and therapeutic decision-making. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This ...
The intersection of artificial intelligence (AI) and healthcare presents a transformative frontier, particularly in the global fight against cancer. As healthcare systems worldwide grapple with rising ...
Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict five-year breast cancer risk from a routine screening mammogram. According to ...
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...
Low-dose computed tomography (LDCT) screening is effective in reducing lung cancer mortality by detecting the disease at earlier, more treatable stages. However, high false-positive rates and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results